INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information

STEVENSON, Md.–(BUSINESS WIRE)–The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) (“SciClone” or the “Company”) relating to the proposed buyout of SciClone by a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CD